Stocktoria
ENANTA PHARMACEUTICALS INC ENTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-03-21
ENANTA PHARMACEUTICALS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M |
| R&D expense | $106.7M | $131.5M | $163.5M | $164.5M | $174.1M |
| Operating income | -$85.3M | -$121.7M | -$137.2M | -$123.8M | -$109.6M |
| Interest expense | — | — | $5.1M | $0 | $0 |
| Income tax | -$1.7M | -$1.7M | $2.8M | -$433,000 | -$28.6M |
| Net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M | -$79.0M |
| EPS (diluted) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 |
| Operating cash flow | -$19.3M | -$78.8M | -$103.2M | -$84.8M | -$70.0M |
| Free cash flow | -$32.2M | -$96.7M | -$112.2M | -$86.9M | -$70.7M |
| Cash & equivalents | $32.3M | $37.2M | $85.4M | $44.0M | $57.2M |
| Total assets | $280.7M | $376.7M | $462.3M | $375.4M | $438.8M |
| Total liabilities | $216.0M | $247.8M | $245.5M | $54.1M | $39.4M |
| Shareholders' equity | $64.7M | $128.8M | $216.7M | $321.3M | $399.4M |
Source: SEC EDGAR filings · CIK 0001177648 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.